Pear Therapeutics announced Tuesday the launch of its FDA-cleared prescription digital therapeutic (PDT) Somryst, making it the first PDT for the treatment of chronic insomnia. The company said Somryst, which is intended for use in patients 22 years and older, will be offered via a fully virtual experience that combines telemedicine with PDT prescribing and dispensation via the PearConnect patient service centre for PDTs.
“We’re excited to offer patients who have been struggling to find a long-term solution for chronic insomnia with a meaningful, first-line treatment that is accessible via an end-to-end care model, to support patients and healthcare providers during the virtual onboarding process,” remarked CEO Corey McCann.
According to Pear Therapeutics, Somryst addresses the underlying issues of chronic insomnia by delivering cognitive behavioural therapy for insomnia. Over six to nine weeks, the programme takes patients through short lessons and challenges, including algorithm-driven sleep restriction, training the brain and body to improve sleep. The programme also provides clinicians with real-time data on patient progress via a physician dashboard.
In clinical trials of more than 1400 adults with chronic insomnia, Somryst was shown to cut the time it took to fall asleep by 45%, decrease the amount of time spent awake at night by 52% and reduce the severity of insomnia symptoms by 45%, with continued improvement at six and 12 months post treatment. Pear Therapeutics is currently undertaking the DREAM study, a virtual real-world trial that will enrol around 350 adults with chronic insomnia for nine weeks of digitally-delivered treatment.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: FirstWord Medtech